Kyorin Pharmaceutical Co (TSE:4569) Common Stock : 円700 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Common Stock?

Kyorin Pharmaceutical Co's quarterly common stock stayed the same from Jun. 2023 (円700 Mil) to Sep. 2023 (円700 Mil) and stayed the same from Sep. 2023 (円700 Mil) to Dec. 2023 (円700 Mil).

Kyorin Pharmaceutical Co's annual common stock stayed the same from Mar. 2022 (円700 Mil) to Mar. 2023 (円700 Mil) and stayed the same from Mar. 2023 (円700 Mil) to Mar. 2024 (円700 Mil).

Kyorin Pharmaceutical Co Common Stock Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Common Stock Chart

Kyorin Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Common Stock

Get a 7-Day Free Trial

700.00

Kyorin Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															700.00	700.00	700.00	700.00	700.00

Kyorin Pharmaceutical Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Kyorin Pharmaceutical Co (TSE:4569) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311

Website

https://www.kyorin-pharm.co.jp

Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines